Loading
Entera Bio Ltd. is a biopharmaceutical firm in the clinical development phase, dedicated to creating and marketing oral medications composed of large molecules, addressing medical conditions that currently lack adequate treatments. Its primary experimental drugs are EB612, currently undergoing Phase II clinical assessment for hypoparathyroidism, and EB613, which has concluded Phase II studies for osteoporosis and is now in Phase I trials for treating non-healing bone fractures. Furthermore, the company holds a collaborative research and licensing pact with Amgen Inc. aimed at identifying and advancing potential therapeutic compounds for inflammatory conditions and other grave ailments. Established in 2009, Entera Bio Ltd. operates from its headquarters in Jerusalem, Israel.
Latest quote
$2.50
−$0.01 · -0.40%
Regular session · ET · Market data may be delayed.
Entera Bio Ltd. is a biopharmaceutical firm in the clinical development phase, dedicated to creating and marketing oral medications composed of large molecules, addressing medical conditions that currently lack adequate treatments. Its primary experimental drugs are EB612, currently undergoing Phase II clinical assessment for hypoparathyroidism, and EB613, which has concluded Phase II studies for osteoporosis and is now in Phase I trials for treating non-healing bone fractures. Furthermore, the company holds a collaborative research and licensing pact with Amgen Inc. aimed at identifying and advancing potential therapeutic compounds for inflammatory conditions and other grave ailments. Established in 2009, Entera Bio Ltd. operates from its headquarters in Jerusalem, Israel.
Day range
Current $2.50
52-week range
Current $2.50
Regular session · ET · Market data may be delayed.
GoAI Score
Sell
Valuation
20
Overpriced
Sentiment
66
Bullish
Risk
72
High Risk
Momentum
44
Neutral
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
Entera Bio Ltd. is a biopharmaceutical firm in the clinical development phase, dedicated to creating and marketing oral medications composed of large molecules, addressing medical conditions that currently lack adequate treatments. Its primary experimental drugs are EB612, currently undergoing Phase II clinical assessment for hypoparathyroidism, and EB613, which has concluded Phase II studies for osteoporosis and is now in Phase I trials for treating non-healing bone fractures. Furthermore, the company holds a collaborative research and licensing pact with Amgen Inc. aimed at identifying and advancing potential therapeutic compounds for inflammatory conditions and other grave ailments. Established in 2009, Entera Bio Ltd. operates from its headquarters in Jerusalem, Israel.
Day range
Current $2.50
52-week range
Current $2.50
Profitability as a percentage of reported revenue.
Revenue
Operating income
Net income
| Metric (USD) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | 42K USD | 181K USD | — | 134K USD | 571K USD |
| Cost of goods sold | 42K USD | 172K USD | 56K USD | 165K USD | 373K USD |
| Gross profit | — | 9K USD | −56K USD | −31K USD | 198K USD |
| Research and development | 6M USD | 4.5M USD | 4.45M USD | 5.78M USD | 6.77M USD |
| Selling, general, and administrative | 5.53M USD | 5.1M USD | 4.43M USD | 7.25M USD | 5.69M USD |
| Operating expenses | 11.53M USD | 9.59M USD | 8.88M USD | 13.04M USD | 12.42M USD |
| Interest income | — | 58K USD | 31K USD | 83K USD | — |
| Interest expense | — | — | — | — | 29K USD |
| Depreciation and amortization | 30K USD | 46K USD | 56K USD | 64K USD | 53K USD |
| Operating income | −11.53M USD | −9.59M USD | −8.94M USD | −13.07M USD | −12.22M USD |
| Net income | −11.44M USD | −9.54M USD | −8.89M USD | −13.07M USD | −12.19M USD |
Company facts updated Oct 8, 2026.
Recent quarterly results
Recent quarterly results
Third-party consensus; not a GoAI recommendation.
Average target
$9.00
260.00% upsideLimited analyst sample: 4 ratings. Interpret the distribution with caution.
AI-generated and delayed market data for informational and educational purposes only. Not investment advice.
